Table 3.
Incident Rate Ratio of Hospitalized AECOPD Visits (High Adherence Vs Poor Adherence) Among COPD Patients During the Follow-Up Period
| Incident Rate Ratio | High Adherence | Poor Adherence | ||||||
|---|---|---|---|---|---|---|---|---|
| Mean | SE | 95% CI | P-value | Predicted Mean | SE | Predicted Mean | SE | |
| Combination ICS/LABA usera | 0.76 | 0.06 | 0.65, 0.87 | <0.001 | 0.55 | 0.04 | 0.73 | 0.03 |
| Inhaled bronchodilator usera | 0.83 | 0.14 | 0.59, 1.17 | 0.28 | 0.49 | 0.06 | 0.59 | 0.06 |
| Oral mucolytic userb | 1.82 | 0.21 | 1.45, 2.29 | <0.001 | 1.69 | 0.19 | 0.92 | 0.02 |
| Test for interactionc,d | — | — | — | <0.001 | — | — | — | — |
Notes: aNegative binomial regression model with the high adherence as the primary exposure and adjusted for age, gender, pre-index AECOPD frequency, Charlson comorbidity index, pre-index theophylline script number, pre-index SABA script number, pre-index LAMA script number, pre-index COPD related cost, and pre-index COPD inpatient visit times for inhaled bronchodilator and ICS/LABA user. bNegative binomial regression model with the high adherence as the primary exposure and adjusted for age, gender, pre-index AECOPD frequency, Charlson comorbidity index, pre-index LABA script number, pre-index SABA script number, pre-index LAMA script number, pre-index COPD related cost, and pre-index COPD inpatient visit times for oral mucolytic user. cNegative binomial regression model with the high adherence as the primary exposure and adjusted for age, gender, pre-index AECOPD frequency, Charlson comorbidity index, pre-index SABA script number, pre-index LAMA script number, pre-index COPD related cost, and pre-index COPD inpatient visit times for the model with interaction. dTest for interaction between drug category and adherence status (high or poor).
Abbreviations: COPD, chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SE, standard error; CI, confidence interval; ICS/LABA, inhaled corticosteroid/long-acting beta-2 agonist; SABA, short-acting beta-agonist; LAMA, long-acting muscarinic antagonist.